AKRO News & Events

Akero Therapeutics announced new findings from the SYMMETRY and HARMONY Phase 2b trials of efruxifermin in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis and pre-cirrhotic MASH, respectively. The data will be shared during two oral and two poster presentations at the 76th Annual American Association for the Study of Liver Diseases, AASLD, The Liver Meeting 2025, taking place November 7-11, 2025. New post-hoc analyses of 96-week data from the SYMMETRY trial reinforce the antifibrotic activity of efruxifermin in F4c MASH: Efruxifermin was associated with statistically significant improvements in clinically significant portal hypertension risk, as assessed by Baveno criteria. CSPH, a serious complication of cirrhosis, increases risk of hepatic complications. Significantly more participants treated with efruxifermin vs. placebo met thresholds for clinically meaningful improvements in noninvasive measures of fibrosis that predict reduced risk of liver-related events. Evaluation of liver biopsies from SYMMETRY using AI-assisted digital pathology corroborated the fibrosis improvements previously demonstrated by conventional pathology and revealed that efruxifermin consistently reduced total fibrosis and septa area, key features of cirrhosis related to disease severity.